Search the Newsreel

Goosehead Insurance (GSHD) trust converts units, sells 5,000 Class A shares

The Chick & The Bear Irrevocable Trust and Adrienne Kebodeaux, part of a 10% owner group of Goosehead Insurance (GSHD), converted 5,000 LLC Units and Class B shares into 5,000 Class A Common Stock shares. Subsequently, they sold these 5,000 Class A shares at …

Arrowhead Pharmaceuticals (ARWR) Could Be 3% Undervalued On Late Stage Trial Progress

Arrowhead Pharmaceuticals (ARWR) appears to be 3% undervalued, according to a recent analysis, following positive late-stage trial data for two RNA interference programs. The company's stock has seen significant momentum, with a 7x return over the past year, driven by reassessments of its risk …

Goosehead Insurance, Inc. Class A Revenue Breakdown – MUN:2OX

This article provides a revenue breakdown for Goosehead Insurance, Inc. Class A (MUN:2OX), detailing its financial performance by segment and geographical contribution. Last year, the company generated €311.03 million, primarily from its Insurance Distribution segment and the United States market.

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones

Arrowhead Pharmaceuticals recently reported that its siRNA drug plozasiran met all primary and key secondary endpoints in two global Phase 3 trials for severe hypertriglyceridemia, while also completing patient enrollment for the YOSEMITE Phase 3 trial of zodasiran in the ultra-rare condition homozygous familial …

Goosehead Insurance (GSHD) insiders plan sale of 250,000 Class A shares

Goosehead Insurance, Inc. (GSHD) has filed a Form 144 indicating a planned sale of up to 250,000 Class A Common shares through J.P. Morgan Securities LLC on or about July 29, 2026. These shares originated from Class B units acquired in 2018 and later …

Bowhead Specialty (NYSE:BOW) Reaches New 52-Week High - Still a Buy?

Bowhead Specialty (NYSE: BOW) recently hit a new 52-week high, trading at $33.20. Despite a reduction in some price objectives by analysts, the company maintains a "Moderate Buy" consensus rating with an average price target of $33.71, based on five Buy and four Hold …

Tuesday’s insider buys and sells: Major transactions revealed

This article details significant insider trading activity on Tuesday, July 29, 2026, across various US public companies. It highlights major insider purchases by Durable Capital Partners LP in Goosehead Insurance, Thomas M. Moriarty in Albertsons Companies, and RA Capital Management in Artiva Biotherapeutics, among …

Equities Analysts Set Expectations for ARWR FY2027 Earnings

Durable capital partners LP buys $9.1m in Goosehead Insurance stock By Investing.com

Durable Capital Partners LP, a significant owner of Goosehead Insurance (NASDAQ:GSHD), recently purchased approximately $9.1 million worth of the company's Class A Common Stock. These acquisitions, totaling 153,723 shares, were made as the stock surged over 15% in the past week. The timing coincides …

Bowhead Specialty Holdings Inc. (BOW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Bowhead Specialty Holdings Inc. (BOW) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026, with an estimated EPS of $0.47 and revenues of $164.29 million. Despite the positive growth outlook, the consensus EPS estimate has been …

Arrowhead Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Arrowhead Pharmaceuticals (ARWR) had 801 employees worldwide as of March 2026, marking a 51.4% growth since 2023. The company is actively hiring, with 152 active job postings in 2026, and its workforce is primarily concentrated in the United States. Revelio Labs data indicates that …

Goosehead Insurance (NASDAQ: GSHD) 10% holder buys 153,723 shares

Durable Capital Partners LP, a ten percent owner of Goosehead Insurance (NASDAQ: GSHD), purchased 153,723 shares of Class A Common Stock through open-market transactions on July 24 and 27, 2026. The shares were acquired at prices ranging from $57.75 to $62.00 per share, totaling …

Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $105.4, Implies 23% Upside

Arrowhead Pharmaceuticals, Inc.'s stock 12-month price target has been increased from $104.7 to $105.4 by analysts, indicating a potential 23% upside from its July 27th closing price. The consensus rating from 14 analysts remains a "Buy," with a range of forecasts from $87 to …

GSHD (GSHD) insider files to sell 10,000 Class A shares via Form 144

An insider at Goosehead Insurance, Inc. (GSHD) has filed a Form 144 to sell 10,000 shares of Class A common stock through J.P. Morgan Securities LLC on or after July 28, 2026. These shares, valued at an aggregate market value of $650,000, were originally …

Insider plans sale of 5,000 GSHD (NASDAQ: GSHD) Class A shares

An insider plans to sell 5,000 Class A Common Stock shares of Goosehead Insurance, Inc. (NASDAQ: GSHD) through J.P. Morgan Securities LLC, starting on or after July 28, 2026. The aggregate market value of these shares is $325,000, and they represent a conversion from …

Bowhead Specialty (BOW) to Announce Earnings on Tuesday

Bowhead Specialty (BOW) is slated to release its Q2 2026 earnings before market open on Tuesday, August 4th, with analysts forecasting earnings of $0.47 per share and revenue of $278.7 million. The company surpassed earnings estimates in its last quarter but fell short on …

REG - Bradda Head Lithium - Result of WRAP Retail Offer

Arrowhead Pharmaceuticals (ARWR) Expected to Announce Earnings on Tuesday

Headwater Exploration (TSX:HWX) Advances Canadian Energy Operations

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals has completed enrollment in its global Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNAi therapeutic targeting homozygous familial hypercholesterolemia (HoFH). The study, which enrolled 70 patients, is expected to be completed in mid-2027, after which Arrowhead plans to seek regulatory …

BOW|Bowhead Specialty Holdings Inc|Price:32.230|Chg%:+1.020

This article provides a comprehensive stock analysis of Bowhead Specialty Holdings Inc (BOW) by TradingKey, highlighting its "fairly valued" status and significant growth potential despite weak fundamentals and technicals that don't fully support the current positive trend. It notes high institutional ownership and multiple …

Bowhead Specialty Holdings Inc. Revenue Breakdown – NYSE:BOW

Bowhead Specialty Holdings Inc. (NYSE: BOW) generated $862.81 million in revenue last year, with its Casualty segment being the top performer at $366.30 million. The United States was its largest regional contributor, accounting for $551.59 million of the revenue. This data highlights the company's …

Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial

Arrowhead Pharmaceuticals announced the completion of enrollment for its Phase 3 YOSEMITE clinical trial for zodasiran, an investigational RNA interference treatment for homozygous familial hypercholesterolemia (HoFH). While this is a significant milestone, the company's financial metrics reflect challenges in profitability and growth, with a …

Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients

Arrowhead Pharmaceuticals announced the completion of enrollment for its global Phase 3 YOSEMITE clinical trial of zodasiran, an investigational RNA interference therapeutic for homozygous familial hypercholesterolemia (HoFH). The study, which initially aimed for 60 participants but enrolled 70 due to strong interest, is expected …

5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%

(RTTNews) - "If you aren't willing to own a stock for 10 years, don't even think about owning it for 10 minutes." - Warren Buffett. The Oracle of Omaha's timeless advice reminds us that patience is one of the key principles of investing. The …

Bowhead Specialty Holdings Inc (BOW) Cash Flow

This article provides a detailed look at the cash flow statement for Bowhead Specialty Holdings Inc (BOW), covering operating, investing, and financing cash flows on quarterly and annual bases. It includes historical data, year-over-year changes, and addresses frequently asked questions about different types of …

Bowhead Specialty Holdings Inc (BOW) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Bowhead Specialty Holdings Inc (BOW), highlighting its current earnings forecast score, average price target of $33.00, and analyst ratings. Based on 8 analysts, the stock has a "Buy" trend. The report also details expected revenue of $168.05M …

Headwater Exploration (TSX:HWX) Reports Strong Quarter With Dividend Maintained

Royal Bank Of Canada Forecasts Strong Price Appreciation for Headwater Exploration (TSE:HWX) Stock

Headwater Exploration (TSX:HWX) Is Up 5.5% After Strong Q2 Results And Dividend Confirmation - What's Changed

1,036,495 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Renaissance Technologies LLC

Weekly Recap: Leadership change to Mark Jones Jr. and Q2 earnings surge

Goosehead Insurance (GSHD) reported a strong Q2 with revenue up 20.6% to $113.4M and adjusted EPS of $0.64. CEO Mark Miller will retire at the end of 2026, handing leadership to President/COO Mark Jones Jr., who plans to focus on technology, distribution, and client …

Bowhead Specialty Holdings Inc (BOW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Bowhead Specialty Holdings Inc (BOW) stock information, focusing on its dividend history. It states that no dividend data is available and that a total of $0.00 has been distributed in dividends over the past five years. The page …

Bowhead Specialty Holdings Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

This article provides a detailed profile of Bowhead Specialty Holdings Inc. (BOW), an insurance holding company specializing in property and casualty insurance products in the United States. It outlines the company's business scope through its subsidiaries, its offerings in casualty, professional liability, and healthcare …

Bowhead Specialty Holdings Inc (BOW) Income Statement

This article provides the quarterly and annual income statements for Bowhead Specialty Holdings Inc (BOW), detailing key financial metrics such as total revenue, operating expenses, operating profit, net income, and earnings per share. It also includes an FAQ section explaining how to read the …

TradingKey

This article provides a detailed balance sheet analysis for Bowhead Specialty Holdings Inc (BOW), covering annual and quarterly financial data from FY2024Q1 to FY2026Q1. It highlights key financial metrics such as cash and cash equivalents, total assets, liabilities, and shareholders' equity, along with percentage …